Anti-CD109 antibody produced in rabbit

CD109 is a member of a family of thioester-containing proteins, called α2-macroglobulin/complement family. It was initially recognized as a leukemia antigen, and is a glycophosphatidylinositol (GPI)-anchored glycoprotein. It is expressed by endothelial cells, platelets, activated T-cells, keratinocytes and certain CD34⁺ hematopoietic stem and progenitor cells. It forms a part of the TGF-β1 receptor complex. This protein has a molecular weight of 180kDa.

CD109 antigen precursor recombinant protein epitope signature tag (PrEST)

All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are supported by the most extensive characterization in the industry.

The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. We also provide Prestige Antibodies^® protocols and other useful information.

The function of CD109 is not well understood. It suppresses the TGF-β/Smad signaling, by promoting the degradation of TGFβ receptor. In scleroderma, it prevents the production of extracellular matrix. It is expressed in esophagus, lung, breast, cervix and urinary tract cancers, and facilitates tumorigenesis in oral cancer. It acts as an antigen for acute myeloid leukemia, and is expressed at the cell surface. It is up-regulated in multiple sarcomas, and has potential as a prognostic marker for epithelioid sarcoma. It is up-regulated in triple-negative breast cancer, and has potential as a marker for the progression and differentiation of breast cancer cells.

Prestige Antibodies^® are highly characterized and extensively validated antibodies with the added benefit of all available characterization data for each target being accessible via the Human Protein Atlas portal linked just below the product name at the top of this page. The uniqueness and low cross-reactivity of the Prestige Antibodies^® to other proteins are due to a thorough selection of antigen regions, affinity purification, and stringent selection. Prestige antigen controls are available for every corresponding Prestige Antibody and can be found in the linkage section.

Every Prestige Antibody is tested in the following ways:

• IHC tissue array of 44 normal human tissues and 20 of the most common cancer type tissues.
• Protein array of 364 human recombinant protein fragments.

Solution in phosphate-buffered saline, pH 7.2, containing 40% glycerol and 0.02% sodium azide

Corresponding Antigen APREST71508

Prestige Antibodies is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.